FDA Proposal Shakes Up Weight-Loss Drug Market for Novo and Lilly

The FDA has proposed excluding weight-loss drugs from Novo Nordisk and Eli Lilly from a key compounding list. This move could limit large-scale production from outsourcing facilities, impacting telehealth firms and supporting Novo and Lilly's efforts to combat unauthorized drug versions affecting sales.

The U.S. Food and Drug Administration has put forth a proposal to exclude the weight-loss drugs of Novo Nordisk and Eli Lilly from a critical compounding list. This proposal could significantly impact the large-scale production capabilities of outsourcing facilities and telehealth companies that rely on them. The measure aims to curb unauthorized versions that threaten the sales of the pharmaceutical giants' popular treatments.

Stock markets reacted favorably, with U.S.-listed shares of Novo Nordisk rising nearly 6% and Eli Lilly seeing a surge of over 10% during afternoon trading. The FDA asserted there is no clinical necessity for outsourcing facilities to compound the active ingredients of Novo's Wegovy and Ozempic, and Lilly's Zepbound and Mounjaro.

The move also addresses Novo's older liraglutide molecule. Both companies expressed approval of the FDA's stance, emphasizing that compounding should be a rare exception within the regulatory drug approval framework. The FDA is reviewing nominations for the 503B bulks list, inviting public comments before finalizing its decision post-June 29.